Composition of Certain Financial Statement Captions |
| | | | | | | | | | | | (In thousands) | September 30, 2022 | | December 31, 2021 | Accounts receivable, net: | | | | Accounts receivable | $ | 129,576 | | | $ | 261,476 | | Less: allowance for credit losses | (6,388) | | | (1,839) | | | $ | 123,188 | | | $ | 259,637 | | Inventories, net: | | | | Consumable supplies | $ | 30,211 | | | $ | 39,447 | | Finished products | 37,188 | | | 44,107 | | Work in-process | 2,580 | | | 1,615 | | Raw materials | 6,417 | | | 6,112 | | Less: inventory reserve | (4,967) | | | (4,779) | | | $ | 71,429 | | | $ | 86,502 | | Other current assets and prepaid expenses: | | | | Taxes recoverable | $ | 5,161 | | | $ | 5,598 | | Prepaid expenses | 9,785 | | | 10,641 | | | | | | | | | | | | | | Prepaid insurance | 7,331 | | | 4,383 | | Other receivables | 9,899 | | | 353 | | Other | 6,340 | | | 6,195 | | | $ | 38,516 | | | $ | 27,170 | | Intangible assets, net: | | | | Customer relationships | $ | 309,758 | | | $ | 314,823 | | Technologies | 812,118 | | | 246,101 | | Trade names | 49,713 | | | 49,770 | | | | | | Covenants not to compete | 12,897 | | | 12,920 | | Licenses | 5,969 | | | 5,766 | | Product registrations | 6,119 | | | 6,995 | | Other | 5,483 | | | 6,128 | | Less: accumulated amortization | (366,921) | | | (320,820) | | | $ | 835,136 | | | $ | 321,683 | | Accrued expenses: | | | | Inventory received but not invoiced | $ | 13,545 | | | $ | 40,446 | | Commitments and contingencies | 1,647 | | | 27,819 | | Employee benefits | 45,124 | | | 45,939 | | Contract liabilities | 257 | | | 258 | | Clinical trials | 4,073 | | | 4,867 | | | | | | Contingent consideration | — | | | 487 | | Finance leases short-term | 2,580 | | | 2,257 | | | | | | Professional fees | 1,630 | | | 2,121 | | | | | | | | | | Other | 43,159 | | | 69,299 | | | $ | 112,015 | | | $ | 193,493 | |
| | | | | | | | | | | | (In thousands) | September 30, 2022 | | December 31, 2021 | Other long-term liabilities: | | | | | | | | | | | | Contingent consideration | $ | 1,671 | | | $ | 2,350 | | | | | | Mortgages and other debts payable | 8,970 | | | 2,224 | | Finance leases long-term | 4,350 | | | 2,924 | | Contract liabilities | 136 | | | 208 | | Other | 7,425 | | | 7,356 | | | $ | 22,552 | | | $ | 15,062 | |
|
Changes in Goodwill |
The following table summarizes the changes in Goodwill by reporting unit during the nine months ended September 30, 2022. | | | | | | | | | | | | | | | | | | | | | | | | | | 2022 | | | (In thousands) | Gross goodwill at January 1 | Cumulative impairment at January 1 | | Acquisitions and dispositions | Foreign exchange and other | Balance at September 30 | | | | | | | Pharmaceuticals | | | | | | | | | | | | | CURNA | $ | 4,827 | | $ | (4,827) | | | $ | — | | $ | — | | $ | — | | | | | | | | Rayaldee | 86,554 | | — | | | — | | (11,509) | | 75,045 | | | | | | | | FineTech | 11,698 | | (11,698) | | | — | | — | | — | | | | | | | | ModeX | — | | — | | | 65,865 | | — | | 65,865 | | | | | | | | OPKO Biologics | 139,784 | | — | | | — | | — | | 139,784 | | | | | | | | OPKO Chile | 3,760 | | — | | | — | | (440) | | 3,320 | | | | | | | | OPKO Health Europe | 7,478 | | — | | | — | | (1,018) | | 6,460 | | | | | | | | OPKO Mexico | 100 | | (100) | | | — | | — | | — | | | | | | | | Transition Therapeutics | 3,421 | | (3,421) | | | — | | — | | — | | | | | | | | | | | | | | | | | | | | | Diagnostics | | | | | | | | | | | | | BioReference | 434,809 | | — | | | (151,784) | | — | | 283,025 | | | | | | | | OPKO Diagnostics | 17,977 | | (17,977) | | | — | | — | | — | | | | | | | | | $ | 710,408 | | $ | (38,023) | | | $ | (85,919) | | $ | (12,966) | | $ | 573,499 | | | | | | | | | | | | | | | | | | | | |
|